Goldman Sachs analyst David Roman initiated coverage of Omada Health (OMDA) with a Buy rating and $29 price target Considering the growth trajectory, near-term path to profitability, and below peer valuation, the analyst sees shares offering a “compelling risk/reward” at current levels, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- JPMorgan Issues Buy Rating for Omada Health, Inc. Citing Growth Potential in Underpenetrated $135 Billion Market and Strategic Partnerships
- Omada Health: A Compelling Investment Opportunity in Digital Health with Strong Growth Potential
- Omada Health: Strong Growth Prospects and Path to Profitability with Undervalued Potential
- Opening Day: Jefferson Capital makes public debut in slow week
- Omada Health releases new data on its GLP-1 companion program